This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Maria Blaszczyk, MD; Tadeusz P. Chorzelski, MD; Stefania Jablonska, MD; Janusz Daszynski, MD; Ernst H. Beutner, PhD
Department of Dermatology; Department of Hematology Warsaw Academy of Medicine 02-008 Warsaw, Poland; Departments of Microbiology and Dermatology State University of New York at Buffalo Buffalo, NY 14214

Arch Dermatol. 1989;125(6):843-844.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Guillaume et al¹ reported on a controlled study of the use of plasmapheresis in 40 cases of pemphigus. Both the control and the experimental groups received upward of 0.5 mg/kg/day of prednisolone together with cyclophosphamide. While a few patients received up to 2 mg/kg/day, most were given about 30 mg/d. The 18 patients with pemphigus who were given plasma exchange treatment had 60 mL/kg removed in 4 weeks, a total of 1.5 times their total plasma volume. The comparisons led Guillaume and coworkers to conclude that, under the conditions used, the plasmapheresis had no therapeutic effect and that, since four patients in their experimental group died of sepsis, the plasma exchange poses significant risks for the patients. We agree with the comments of Bystryn² that the indications for plasmapheresis are not as a primary mode of treatment of pemphigus as used by Guillaume et al,¹ but . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?